美国12-17岁人群COVID-19疫苗加强针接种安全性监测(2021年12月9日至2022年2月20日)
CDC分析了2021年12月9日至2022年2月20日期间美国12-17岁青少年接种辉瑞-BioNTech同源加强针后主动监测系统v-safe和被动监测系统VAERS的不良事件报告。VAERS收到914份报告,其中837份(91.6%)为非严重事件,77份(8.4%)为严重事件。
要点
- v-safe报告显示加强针后反应频率等于或略高于第2剂,以轻中度为主,多在接种次日报告。
- VAERS收到914份青少年加强针后不良事件报告,其中严重事件77份(8.4%)。
- CDC建议告知医务人员、家长和青少年,同源辉瑞-BioNTech加强针后局部和全身反应属预期现象,严重不良事件罕见。
核心结论
- 青少年接种同源辉瑞-BioNTech加强针后,局部和全身反应属预期现象,严重不良事件罕见。
研究设计与样本
- CDC审查了2021年12月9日至2022年2月20日期间12-17岁人群接种同源辉瑞-BioNTech加强针后一周内报告至v-safe的不良事件和健康影响评估,以及报告至VAERS的不良事件。
主要发现
- v-safe报告的反应频率等于或略高于第2剂后,以轻中度为主,接种次日报告最多。
- VAERS收到914份青少年加强针后不良事件报告,837份(91.6%)为非严重事件,77份(8.4%)为严重事件。
临床怎么用
- 医务人员、家长和青少年应被告知,青少年接种同源辉瑞-BioNTech加强针后局部和全身反应属预期现象,严重不良事件罕见。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As of February 20, 2022, only BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine has been authorized for use in persons aged 12-17 years in the United States (1). The Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for Pfizer-BioNTech vaccine on December 9, 2021, to authorize a homologous* booster dose for persons aged 16-17 years ≥6 months after receipt of dose 2 (1). On January 3, 2022, authorization was expanded to include persons aged 12-15 years, and for all persons aged ≥12 years, the interval between dose 2 and booster dose was shortened to ≥5 months (1). To characterize the safety of Pfizer-BioNTech booster doses among persons aged 12-17 years (adolescents), CDC reviewed adverse events and health impact assessments during the week after receipt of a homologous Pfizer-BioNTech booster dose reported to v-safe, a voluntary smartphone-based safety surveillance system for adverse events after COVID-19 vaccination, and adverse events reported to the Vaccine Adverse Event Reporting System (VAERS), a passive vaccine safety surveillance system managed by CDC and FDA. During December 9, 2021-February 20, 2022, approximately 2.8 million U.S. adolescents received a Pfizer-BioNTech booster dose.† During this period, receipt of 3,418 Pfizer-BioNTech booster doses were reported to v-safe for adolescents. Reactions were reported to v-safe with equal or slightly higher frequency after receipt of a booster dose than after dose 2, were primarily mild to moderate in severity, and were most frequently reported the day after vaccination. VAERS received 914 reports of adverse events after Pfizer-BioNTech booster dose vaccination of adolescents; 837 (91.6%) were nonserious and 77 (8.4%) were serious. Health care providers, parents, and adolescents should be advised that local and systemic reactions are expected among adolescents after homologous Pfizer-BioNTech booster vaccination, and that serious adverse events are rare.
引用
- Hause AM, Baggs J, Marquez P, et al. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35239637. doi:10.15585/mmwr.mm7109e2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。